Ocumetics Technology Announces Amendment to Brokered LIFE Offering Led by Centurion One Capital

(TheNewswire)

Calgary, AB – TheNewswire - December 19, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the“Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) announces that further to its previously announced (November25, 2025) brokered private placement (the “Offering”) on abest-efforts basis led by Centurion One Capital Corp. (the“Lead Agent”), the Corporation has amended theterms of the Offering.

Pursuant to the amended terms, up to 4,166,666 units ofthe Corporation (“Units”) will now be issued at an amendedissue price of $0.60 per Unit (the “Amended Issue Price”) for aggregate gross proceeds of up to $2,500,000. EachUnit shall consist of one common share in the capital of theCorporation (each, a “Share”) and one common share purchasewarrant (each, a “Warrant”). EachWarrant will entitle the holder thereof to acquire one common share ofthe Corporation (each, a “Warrant Share”) at an exercise price of$0.75 per Warrant Share at any time for a period of three (3) yearsfollowing the Closing Date (as defined herein).

In addition, the Corporation will now grant the LeadAgent an option to sell up to an additional 625,000 Units at theAmended Issue Price for additional gross proceeds of up to $375,000(the “Agent’sOption”) on the same terms and conditions asset out herein. The Agent’s Option is exercisable in whole or inpart at any time up to two business days prior to the Closing Date.

The gross proceeds of the Offering are expected to beused to fund the Corporation’s first-in-human clinical trials, forongoing research and development and for general corporate purposes. Although the Corporation intends to use the proceeds of the offeringas described above, the actual allocation of proceeds may vary fromthe uses set out above, depending upon future operations, events oropportunities.

The Units will be offered for sale (i) by way ofprivate placement pursuant to the listed issuer financing exemptionunder section 5A.2 of National Instrument 45-106 – Prospectus Exemptions, as amended and supplemented by Coordinated Blanket Order45-935 – Exemptions fromCertain Conditions of the Listed Issuer FinancingExemption (the “Listed Issuer FinancingExemption”) in British Columbia, Alberta andOntario, (ii) in the United States pursuant to an exemption from theregistration requirements of the United States Securities Act of 1933,as amended (the “U.S.Securities Act”), and applicable U.S. statesecurities laws, and (iii) in jurisdictions outside of Canada and theUnited States as mutually agreed to by the Corporation and the LeadAgent, provided it is understood that no prospectus filing,registration or comparable obligation arises in such otherjurisdiction. The securities issued under the Listed Issuer FinancingExemption will not be subject to a statutory hold period pursuant toapplicable Canadian securities laws.

There is an amended and restated offering document (the“OfferingDocument”) related tothis Offering that can be accessed under the Corporation’s profileat www.sedarplus.ca and on the Corporation’s website atwww.ocumetics.com. Prospective investors should read this OfferingDocument before making an investment decision.

The Offering is expected to close on or around December29, 2025, or such other date as agreed upon between the Corporationand the Lead Agent (the “Closing Date”) and is subject to certainconditions, including, but not limited to, the receipt of allnecessary approvals including the approval of the TSX Venture Exchange(the “Exchange”).

It is anticipated that certain insiders of theCorporation, the Lead Agent and certain affiliates may acquire Unitsin the Offering. Any participation by insiders in the Offering willconstitute a "related party transaction" as defined underMultilateral Instrument 61-101 – Protection of Minority Security Holders inSpecial Transactions ("MI 61-101"). TheCorporation expects such participation will be exempt from theformal valuation and minority shareholderapproval requirements of MI 61-101 as neither the fair market value ofthe Units subscribed for by the insiders, nor the consideration forthe Units paid by such insiders, is expected to exceed 25% of theCorporation's market capitalization.

This news release does not constitute an offer to sellor a solicitation of an offer to buy any of the securities in theUnited States. The securities have not been and will not be registeredunder the U.S. Securities Act or any state securities laws and may notbe offered or sold within the United States or to U.S. persons unlessregistered under the U.S. Securities Act and applicable statesecurities laws or an exemption from such registration isavailable.

ABOUT OCUMETICS

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF)(FRA: 2QB0) is a Canadian research and product development companythat is dedicated to developing advanced vision correction solutionsthat enhance the quality of life for patients. Through innovativeresearch and development, Ocumetics aims to transform the field ofophthalmology with state-of-the-art intraocular lenses and othervision-enhancing technologies.

Ocumetics is in the preclinical study stage of agame-changing technology for the ophthalmic industry. Ocumetics hasdeveloped an intraocular lens that fits within the natural lenscompartment of the eye potentially to eliminate the need forcorrective lenses. It is designed to allow the eye’s natural muscleactivity to shift focus from distance to near, providing clear visionat all distances without the help of glasses or contact lenses.

Additional information is available atwww.ocumetics.com and www.sedarplus.ca.

For further information, please contact:

Mr. Dean Burns

President and CEO

Tel: 817-874-7564

About Centurion One Capital

Centurion One Capital's mission is to ignite theworld's most visionary entrepreneurs to conquer the greatestchallenges of tomorrow, fueling their ambitions with transformativecapital, unparalleled expertise, and a global network of influentialconnections. Every interaction is guided by our core values ofrespect, integrity, commitment, excellence in execution, anduncompromising performance. We make principal investments, drawing onthe time-honored principles of merchant banking, where alignedincentives forge enduring partnerships. Centurion One Capital: Asuperior approach to investment banking.

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this release.

CAUTIONARY NOTE REGARDINGFORWARD-LOOKING STATEMENTS:

This news release contains certain “forward-lookinginformation” within the meaning of applicable Canadian securitieslegislation. Generally, forward-lookinginformation can be identified by the use of forward-lookingterminology such as “plans”, “expects” or “does notexpect”, “is expected”, “budget”, “scheduled”,“estimates”, “forecasts”, “intends”, “anticipates” or“does not anticipate”, or “believes”, or variations of suchwords and phrases or state that certain actions, events or results“may”, “could”, “would”, “might” or “will betaken”, “occur” or “be achieved”. Forward-looking statements include, but are not limited to,statements with respect to the completion of theOffering and the anticipated ClosingDate thereof; the expected receipt of regulatoryand Exchange approvals relating to the Offering; the expected proceedsof the Offering and the anticipated use thereof; and any otheractivities, events or developments that the companies expect oranticipate will or may occur in the future.

Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances. There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements. The Corporationdisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise, except as required by law.

NOT FORDISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATIONIN THE UNITED STATES

Copyright (c) 2025 TheNewswire - All rights reserved.